Mammographic fibroglandular density of breast
ICD-10 R92.32 is a billable code used to indicate a diagnosis of mammographic fibroglandular density of breast.
Mammographic fibroglandular density refers to the composition of breast tissue as seen on a mammogram, where dense fibroglandular tissue appears white on the imaging, potentially obscuring lesions. High fibroglandular density is associated with an increased risk of breast cancer, making it a significant finding in breast imaging. This density can vary among individuals and is influenced by factors such as age, hormonal status, and genetic predisposition. Clinically, patients may not present with specific symptoms related to fibroglandular density; however, it is often identified incidentally during routine mammography screenings. The assessment of breast density is crucial for determining the appropriate screening strategies and follow-up imaging, as dense breasts may require additional imaging modalities, such as ultrasound or MRI, to ensure comprehensive evaluation. Understanding the implications of fibroglandular density is essential for both patient management and risk assessment in breast cancer screening protocols.
Documentation should include the patient's history, risk factors for breast cancer, and any previous imaging results. Clear notes on the assessment of breast density and recommendations for follow-up imaging are essential.
Routine screening mammograms where fibroglandular density is noted, and patients with a family history of breast cancer.
Consideration of the patient's age and hormonal status is important, as these factors influence breast density.
Documentation must include the reason for imaging, any acute symptoms, and findings related to breast density. If the patient presents with breast pain or other symptoms, these should be clearly documented.
Patients presenting with breast pain or palpable masses requiring urgent imaging.
Emergency settings may require rapid assessment and clear communication of findings to ensure appropriate follow-up.
Used when performing a mammogram that reveals fibroglandular density.
Documentation of the mammogram results and any recommendations for follow-up imaging.
Radiology specialists should ensure clear communication of findings to referring providers.
It indicates the composition of breast tissue, which can affect the visibility of lesions on mammograms and is associated with an increased risk of breast cancer.
